Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell-based products and therapies. The Berkeley Lights platform can streamline laboratory setups by using fewer machines while working with thousands of cells at once to exponentially increase workflow speed.

Berkeley Lights technology is based on developing a detailed understanding of cell functionality prior to spending time and resources experimenting and engineering an inferior cell. The technology is essentially “pre-screening” cells for detailed background checks to avoid mis-pairing poorly performing cells for the inherently wrong tasks. The pre-screening is done through an opto fluidic platform that characterizes the phenotypic and genotypic data on cells. This information is subsequently aggregated into a database profiling each cell for biotech companies to assess best candidates for a particular job. Berkeley Lights technology is currently used in three market segments $6 billion in antibody therapeutics, $15 billion in cell therapy, and $2 billion in synthetic biology.